Effects of Fuzheng Huayu Tablets on COVID-19
Novel Coronavirus Pneumonia
About this trial
This is an interventional treatment trial for Novel Coronavirus Pneumonia
Eligibility Criteria
Inclusion Criteria:
Patients were included if they (1) had COVID-19; (2) were 18 to 65 years old; (3) did not participate in other drug clinical studies within 1 month before enrollment; and (4) voluntarily accepted treatment and signed an informed consent form.
Exclusion Criteria:
Patients were excluded if they (1) had critical COVID-19; (2) were unconsciousness, had dementia, had psychiatric conditions, or were unable to communicate normally; (3) had severe cardiac insufficiency (i.e., cardiac function grade IV), severe liver or kidney disease, bronchial asthma, COPD, neurological disease, tumor, thoracic deformity, or immunodeficiency disease; (4) were pregnant or lactating or had a recent pregnancy plan; and (5) had a known allergy to any treatment drug.
Sites / Locations
- Shuguang Hospital
Arms of the Study
Arm 1
Arm 2
Experimental
No Intervention
FZHY Group
Control Group
conventional therapy plus Fuzheng Huayu tablet (0.4g/tablet, 1.6g/time, 3 times/day, oral; take medicine after meals each time.)
conventional therapy